Previous 10 | Next 10 |
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial M...
2023-11-21 16:09:06 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials For further details see: Sutro Biopharma appoints Chung as its COO
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chi...
2023-11-14 10:04:00 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
Sutro Biopharma Inc. (STRO) is expected to report $-0.76 for Q3 2023
2023-11-13 17:41:08 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials For further details see: Sutro Biopharma GAAP EPS of -$0.81, revenue of $16.9M
2023-11-13 17:36:19 ET More on Sutro Biopharma Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching Sutro BioPharma: Good Stewardship Through Early Trials Sutro gains as Oppenheimer sees 200% upside on ADC potential Seeking Alpha’...
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - - Luvelta demonstrated encouraging preliminary anti-tumor activity in initial data from th...
- Luvelta demonstrate d encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression – - Safety profile was consistent with prior data ...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations an...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...